Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Interventions
DRUG

mifepristone

Trial Locations (22)

19001

Rosenfeld Cancer Center at Abington Memorial Hospital, Abington

19010

Bryn Mawr Hospital, Bryn Mawr

19096

Lankenau Cancer Center at Lankenau Hospital, Wynnewood

39581

Regional Cancer Center at Singing River Hospital, Pascagoula

44060

Lake/University Ireland Cancer Center, Mentor

54449

Marshfield Clinic - Marshfield Center, Marshfield

60521

Hinsdale Hematology Oncology Associates, Hinsdale

64804

Freeman Cancer Institute at Freeman Health System, Joplin

65807

Hulston Cancer Center at Cox Medical Center South, Springfield

68114

Methodist Estabrook Cancer Center, Omaha

70815

Woman's Hospital, Baton Rouge

73104

Oklahoma University Cancer Institute, Oklahoma City

90027

Kaiser Permanente Medical Center - Los Angeles, Los Angeles

06105

Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford

06050

George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus, New Britain

04102

Maine Medical Center - Bramhall Campus, Portland

08043

Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees Township

44106-5065

Case Comprehensive Cancer Center, Cleveland

43214-3998

Riverside Methodist Hospital Cancer Care, Columbus

19301-1792

Cancer Center of Paoli Memorial Hospital, Paoli

02905

Women and Infants Hospital of Rhode Island, Providence

77555-0361

University of Texas Medical Branch, Galveston

All Listed Sponsors
lead

Gynecologic Oncology Group

NETWORK

NCT00459290 - Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | Biotech Hunter | Biotech Hunter